The global biomarkers market was valued at USD 77.56 billion in 2024 and is expected to rise to USD 86.95 billion in 2025. It is projected to reach USD 193.97 billion by 2032, reflecting a robust CAGR of 12.1% during the forecast period. In 2024, North America held the largest share of the biomarkers market, accounting for 37.06% of the global revenue.
The biomarkers market is witnessing steady growth as advancements in diagnostics, drug discovery, and personalized medicine drive adoption across healthcare. Growing demand for early disease detection, rising investment in clinical research, and the integration of genomics, proteomics, and bioinformatics are strengthening the role of biomarkers in oncology, cardiology, neurology, and infectious diseases. While factors such as high development costs, regulatory hurdles, and data management challenges restrain the market, opportunities remain strong in emerging regions with expanding healthcare infrastructure and increasing awareness. North America and Europe continue to dominate due to advanced R&D and healthcare systems, while Asia-Pacific is expected to register the fastest growth, supported by large patient populations and rising pharmaceutical activity. Overall, the biomarkers market is poised for sustained expansion, driven by innovation and the shift toward precision medicine.
Continue reading for more details:
https://www.fortunebusinessinsights.com/biomarkers-market-102173
Market Size & Forecast
The global biomarkers market was valued at USD 77.56 billion in 2024 and is expected to grow to USD 86.95 billion in 2025.
By 2032, the market is projected to reach USD 193.97 billion, registering a CAGR of 12.1% from 2025 to 2032.
Market growth is driven by increasing demand for precision medicine, expansion in clinical research, and the rising use of biomarkers in drug development and disease diagnostics.
Market Share
North America led the global biomarkers market in 2024, accounting for 37.06% of total market share.
Growth in the region is fueled by:
Widespread adoption of personalized medicine.
Strong investment from biopharmaceutical companies in biomarker discovery.
A well-established healthcare infrastructure and favorable reimbursement environment.
By Indication:
Oncology was the leading segment in 2024 and is anticipated to maintain its dominance.
This is supported by the increasing global cancer burden and the expanding role of biomarkers in cancer diagnostics, prognosis, and targeted therapies.
Key Country Highlights
Japan:
Rising use of biomarkers in oncology and neurology research.
Supported by government-backed precision medicine initiatives and academic-industry collaborations.
United States:
A key contributor to market growth, driven by:
High levels of R&D investment in biomarker technologies.
Growing adoption of companion diagnostics.
Expedited regulatory pathways for biomarker-based therapies and clinical trials.
China:
Growth is driven by increasing rates of cancer and cardiovascular diseases.
Ongoing healthcare reforms and expanding investments in biomarker-based drug development are strengthening the local market landscape.
Europe:
The market benefits from:
A robust clinical research ecosystem.
Supportive regulations, particularly the EU’s In-Vitro Diagnostic Regulation (IVDR) framework.
Cross-sector partnerships between biotech firms and healthcare institutions to advance biomarker applications.
Market Segmentation
By Type: Includes safety biomarkers, efficacy biomarkers, and validation biomarkers, widely applied in drug discovery and disease monitoring.
By Application: The biomarkers market is segmented into diagnostics, drug discovery & development, personalized medicine, and disease risk assessment.
By Disease Area: Covers oncology, cardiovascular diseases, neurological disorders, infectious diseases, and autoimmune diseases.
By End-user: Pharmaceutical & biotechnology companies, diagnostic centers, research institutes, and hospitals play a major role in the biomarkers market.
By Technology: Genomics, proteomics, metabolomics, imaging, and bioinformatics support diverse biomarker applications.
List Of Key Companies Covered:
Hoffmann-La Roche Ltd.
Abbott
Thermo Fisher Scientific
Bio-Rad Laboratories, Inc.
CENTOGENE N.V.
Axon Medchem
Sino Biological Inc.,
R&D System
BioVision Inc.
Myriad RBM
Other players
Market Growth
The biomarkers market is witnessing robust expansion due to increasing applications in diagnostics, drug discovery, and personalized medicine.
Rising demand for early disease detection and precision healthcare is fueling the growth of the biomarkers market.
Technological advancements in genomics and proteomics are accelerating the adoption of biomarker-based solutions across healthcare systems.
Increasing clinical trials that incorporate biomarker validation are further propelling the biomarkers market growth.
Investments by pharmaceutical and biotechnology companies are strengthening the market landscape for biomarkers.
Restraining Factors
High costs associated with biomarker validation and development processes act as a major barrier in the biomarkers market.
Regulatory challenges and lack of standardization across biomarker-based studies limit market penetration.
Complex and time-consuming clinical trials reduce the speed of biomarker commercialization.
Limited reimbursement policies for biomarker-based diagnostics can hinder broader adoption.
Ethical issues and data privacy concerns in genetic biomarker research restrict the potential of the biomarkers market.
Regional Analysis
North America holds a significant share of the biomarkers market due to advanced healthcare infrastructure, high R&D investment, and strong adoption of personalized medicine.
Europe shows steady growth in the biomarkers market, supported by government funding for clinical research and adoption of advanced diagnostic tools.
Asia-Pacific is emerging as the fastest-growing region, driven by large patient populations, increasing healthcare investments, and growing pharmaceutical research.
The biomarkers market in Latin America is expanding with rising demand for advanced diagnostics and clinical trials.
The Middle East & Africa region shows gradual growth, with improving healthcare infrastructure and increasing biomarker adoption for disease management.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
9th Floor, Icon Tower,
Baner - Mahalunge Road,
Baner, Pune-411045, Maharashtra, India.
Phone: U.S.: +1 424 253 0390
U.K.: +44 2071 939123
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com